PMCTPharmaCountry
    Startseite

Regulatorische Updates

Regulatorische Entwicklungen von FDA, EMA, TGA und weltweit

#Lilly ×

UPDATED
Regulatorische Updates
5. Sept. 2026•1 Min. Lesezeit
FDA Approves NDA007392 for Secobarbital Sodium Injection (Seconal)
FDA has approved NDA007392 for Seconal Sodium injectable, a secobarbital sodium product by Lilly, with a detailed submission history and discontinued marketing status.
1
UPDATED
Regulatorische Updates
30. Aug. 2026•1 Min. Lesezeit
FDA Approves Lilly Methyltestosterone Tablet ANDA080256 (Discontinued)
FDA approved Lilly's ANDA080256 for methyltestosterone tablets (10 mg and 25 mg) buccal/sublingual on Dec 22 1971; both products are now discontinued.